GlassScriptPhysician profile
Oussama Hajal
NPI 1811585730
$3,363.20
in general payments reported to CMS, 2019-2025
23 companies · $22.56 in 2025
The $22.56 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $840 · 2022: $1,535 · 2023: $841 · 2024: $125 · 2025: $22.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $910.56 | 2021-2023 | Glassia |
| Astrazeneca Pharmaceuticals LP | $819.61 | 2021-2024 | Tezspire, Farxiga |
| Glaxosmithkline, LLC. | $335.13 | 2022-2023 | Nucala |
| Regeneron Healthcare Solutions, INC. | $215.65 | 2021-2023 | Dupixent |
| Pfizer INC. | $207.33 | 2021-2023 | |
| Amgen INC. | $150.51 | 2021-2023 | Otezla, Repatha |
| United Therapeutics Corporation | $139.65 | 2021 | |
| Horizon Therapeutics Plc | $133.15 | 2023 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $95.22 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.27 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $43.54 | 2023 | Purified Cortrophin Gel |
| Abbvie INC. | $40.37 | 2021-2022 | |
| Exact Sciences Corporation | $28.43 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $22.56 | 2025 | General - Pain Management |
| Novo Nordisk INC | $18.18 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $17.79 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.87 | 2021 | |
| Abbott Laboratories | $16.52 | 2021 | |
| Electromed, INC. | $16.45 | 2023 | Smartvest |
| Xeris Pharmaceuticals, INC. | $16.06 | 2022 | |
| Optinose US, INC. | $14.26 | 2022 | |
| Eisai INC. | $14.03 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $10.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oussama Hajal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.